Posted by Michael Wonder on 18 Jan 2023
PHARMAC seeking feedback on funding a second spinal muscular atrophy treatment
19 January 2023 - PHARMAC is initiating a consultation today, seeking feedback on a proposal to fund of risdiplam (Evrysdi) for people with the rare genetic disorder spinal muscular atrophy, who meet the eligibility criteria.
If approved, funding would start from 1 May 2023.
